Congress Revisits Pharmaceutical Patent Reform Amid “Thicket” Debate

In December, Congress briefly included, then removed, a provision in a proposed spending bill that aimed to curtail the number of patents pharmaceutical companies could leverage in legal disputes. This decision comes as discussions intensify over the concept of “patent thickets”—where companies obtain large numbers of patents to stifle competition. As legislative efforts may resurface this year, it is crucial that any potential actions be informed by precise data, such as the findings from a recent U.S. Patent and Trademark Office study. This study reportedly concluded that there is a lack of evidence supporting the existence of patent thicketing in the pharmaceutical industry, according to David Kappos of the Council for Innovation Promotion.